<table id="ID125" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col span="1" width="21%"></col>
<col span="1" width="14%"></col>
<col span="1" width="24%"></col>
<col span="1" width="8%"></col>
<col span="1" width="8%"></col>
<col span="1" width="8%"></col>
<col span="1" width="17%"></col>
<tbody>
<tr>
<td>
<content stylecode="bold">Table </content>
<content stylecode="bold">6</content>
<content stylecode="bold">: </content>
<content stylecode="bold">Clarithromycin </content>
<content stylecode="bold">Susceptibility </content>
<content stylecode="bold">Test </content>
<content stylecode="bold">Results </content>
<content stylecode="bold">and </content>
<content stylecode="bold">Clinical </content>
<content stylecode="bold">/ </content>
<content stylecode="bold">
<br/>
</content>
<content stylecode="bold">Bacteriological </content>
<content stylecode="bold">Outcomes</content>
<content>*</content>
<br/>
</td>
</tr>
<tr>
<td>Clarithromycin Pretreatment <br/>Results <br/>
</td>
<td>Clarithromycin Post-treatment Results<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>
<content stylecode="italics">H</content>
<content stylecode="italics">. </content>
<content stylecode="italics">pylori </content>negative -eradicated<br/>
</td>
<td>
<content stylecode="italics">H</content>
<content stylecode="italics">. </content>
<content stylecode="italics">pylori </content>positive – not eradicated <br/>Post-treatment susceptibility results<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>S<sup>†</sup>
<br/>
</td>
<td>I<sup>†</sup>
<br/>
</td>
<td>R<sup>†</sup>
<br/>
</td>
<td>No MIC<br/>
</td>
</tr>
<tr>
<td>Triple Therapy 14-Day (lansoprazole 30 mg twice daily/amoxicillin <br/>1 g twice daily/clarithromycin 500 mg twice daily) <br/>(M95-399, M93-131, M95-392) <br/>
</td>
</tr>
<tr>
<td>Susceptible<sup>†</sup> <br/>
</td>
<td>112<br/>
</td>
<td>105<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>7<br/>
</td>
</tr>
<tr>
<td>Intermediate<sup>†</sup> <br/>
</td>
<td>3<br/>
</td>
<td>3<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Resistant<sup>†</sup> <br/>
</td>
<td>17<br/>
</td>
<td>6<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>7<br/>
</td>
<td>4<br/>
</td>
</tr>
<tr>
<td>Triple Therapy 10-Day (lansoprazole 30 mg twice daily/amoxicillin <br/>1 g twice daily/clarithromycin 500 mg twice daily) (M95-399) <br/>
</td>
</tr>
<tr>
<td>Susceptible<sup>†</sup> <br/>
</td>
<td>42<br/>
</td>
<td>40<br/>
</td>
<td>1<br/>
</td>
<td>
<br/>
</td>
<td>1<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Intermediate<sup>†</sup> <br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Resistant<sup>†</sup> <br/>
</td>
<td>4<br/>
</td>
<td>1<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>3<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>
<paragraph>
<sup>*</sup>Includes only patients with pretreatment clarithromycin susceptibility test results<br/>
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<sup>†</sup>Susceptible (S) MIC ≤0.25 mcg/mL, Intermediate (I) MIC 0.5 to 1 mcg/mL, Resistant (R) MIC ≥2 mcg/mL<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>